×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BTAI – bioxcel therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BTAI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/12
07:00 am
btai
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
Medium
Report
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
11/8
07:00 am
btai
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
Medium
Report
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
11/5
12:13 pm
btai
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know [Yahoo! Finance]
Low
Report
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know [Yahoo! Finance]
10/29
07:00 am
btai
BioXcel Therapeutics to Present at ThinkEquity Conference
Medium
Report
BioXcel Therapeutics to Present at ThinkEquity Conference
10/21
08:07 am
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "buy" rating on the stock.
10/15
07:00 am
btai
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
Medium
Report
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
9/19
07:00 am
btai
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
Low
Report
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
9/6
08:08 am
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
High
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
8/6/2024
07:00 am
btai
bioxcel therapeutics, inc.
BEAT
Report
1.7%
bioxcel therapeutics, inc.
5/9/2024
07:00 am
btai
bioxcel therapeutics, inc.
MISS
Report
0.2%
bioxcel therapeutics, inc.
3/12/2024
07:00 am
btai
bioxcel therapeutics, inc.
BEAT
Report
-7.7%
bioxcel therapeutics, inc.
11/14/2023
07:00 am
btai
bioxcel therapeutics, inc.
MISS
Report
-21.0%
bioxcel therapeutics, inc.
Date
Time
Symbol
Headline
Impact
10/9
04:08 pm
btai
Form 8-K BioXcel Therapeutics, For: Oct 03
Medium
Report
Form 8-K BioXcel Therapeutics, For: Oct 03
10/3
09:56 pm
btai
Form 4 BioXcel Therapeutics, For: Sep 17 Filed by: Wiley Matthew T.
Medium
Report
Form 4 BioXcel Therapeutics, For: Sep 17 Filed by: Wiley Matthew T.
10/3
09:55 pm
btai
Form 4 BioXcel Therapeutics, For: Sep 17 Filed by: Yocca Frank
Medium
Report
Form 4 BioXcel Therapeutics, For: Sep 17 Filed by: Yocca Frank
10/3
09:55 pm
btai
Form 4 BioXcel Therapeutics, For: Sep 17 Filed by: Rodriguez Javier
Medium
Report
Form 4 BioXcel Therapeutics, For: Sep 17 Filed by: Rodriguez Javier
10/3
09:54 pm
btai
Form 4 BioXcel Therapeutics, For: Sep 17 Filed by: O'Neill Vincent
Medium
Report
Form 4 BioXcel Therapeutics, For: Sep 17 Filed by: O'Neill Vincent
10/3
09:54 pm
btai
Form 4 BioXcel Therapeutics, For: Sep 17 Filed by: Steinhart Richard I
Medium
Report
Form 4 BioXcel Therapeutics, For: Sep 17 Filed by: Steinhart Richard I
10/3
04:40 pm
btai
Form 144 BioXcel Therapeutics, Filed by: Rodriguez Javier
Medium
Report
Form 144 BioXcel Therapeutics, Filed by: Rodriguez Javier
10/3
04:33 pm
btai
Form 144 BioXcel Therapeutics, Filed by: Wiley Matthew T.
Medium
Report
Form 144 BioXcel Therapeutics, Filed by: Wiley Matthew T.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/31
BioXcel Therapeutics Inc (NASDAQ: BTAI) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $25.00 price target on the stock.
40.3%
2/14 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at SunTrust Banks, Inc. to $150.00. They now have a "buy" rating on the stock. 19.3%
2/5 BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms 16.0%
8/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 14.4%
1/16 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at BMO Capital Markets to $26.00. They now have a "positive" rating on the stock. 14.4%
3/19 BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials 12.9%
4/28 Form 4 BioXcel Therapeutics, For: Jan 02 Filed by: Nandabalan Krishnan 10.7%
4/6 Form DEF 14A BioXcel Therapeutics, For: May 20 9.9%
2/26 BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor Conferences 9.7%
1/13 Form 8-K BioXcel Therapeutics, For: Jan 13 9.5%
2/14 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at SunTrust Banks, Inc. to $150.00. They now have a "buy" rating on the stock. 19.3%
2/5 BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms 16.0%
8/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 14.4%
1/16 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at BMO Capital Markets to $26.00. They now have a "positive" rating on the stock. 14.4%
3/19 BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials 12.9%
4/28 Form 4 BioXcel Therapeutics, For: Jan 02 Filed by: Nandabalan Krishnan 10.7%
4/6 Form DEF 14A BioXcel Therapeutics, For: May 20 9.9%
2/26 BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor Conferences 9.7%
1/13 Form 8-K BioXcel Therapeutics, For: Jan 13 9.5%
TOP News Decliners
3/14
BioXcel Therapeutics Inc (NASDAQ: BTAI) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.
-26.4%
9/25 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -23.5%
3/2 BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast -21.3%
5/12 BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -14.7%
2/19 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -14.5%
3/9 BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update -10.3%
3/10 BioXcel Therapeutics (BTAI) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -9.3%
10/18 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.6%
5/9 BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference -8.3%
1/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock, up previously from $25.00. -8.1%
9/25 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -23.5%
3/2 BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast -21.3%
5/12 BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -14.7%
2/19 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -14.5%
3/9 BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update -10.3%
3/10 BioXcel Therapeutics (BTAI) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -9.3%
10/18 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.6%
5/9 BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference -8.3%
1/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock, up previously from $25.00. -8.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: